{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:58:52Z","timestamp":1791939532298,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18lm0203066h0001"],"award-info":[{"award-number":["18lm0203066h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21lm0203086h0003"],"award-info":[{"award-number":["21lm0203086h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xcrm.2024.101901","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T15:32:58Z","timestamp":1736436778000},"page":"101901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase 1\/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"6","author":[{"given":"Hirofumi","family":"Komaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-7002","authenticated-orcid":false,"given":"Katsuhiko","family":"Kunitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takami","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shimizu-Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Yonee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-7506","authenticated-orcid":false,"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101901_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101901_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.xcrm.2024.101901_bib3","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101901_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.xcrm.2024.101901_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101901_bib8","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-Skipping in Duchenne Muscular Dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.xcrm.2024.101901_bib10","doi-asserted-by":"crossref","first-page":"25ps15","DOI":"10.1126\/scitranslmed.3000512","article-title":"Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge","volume":"2","author":"Wood","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101901_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2024.101901_bib12","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0960-8966(02)00086-X","article-title":"Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy","volume":"12","author":"Aartsma-Rus","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2024.101901_bib13","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"27","author":"Echevarr\u00eda","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2024.101901_bib14","doi-asserted-by":"crossref","first-page":"164ra160","DOI":"10.1126\/scitranslmed.3005054","article-title":"Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy","volume":"4","author":"Kendall","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101901_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles","volume":"102","author":"Qi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101901_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101901_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2024.101901_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/mt.2010.186","article-title":"In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse","volume":"18","author":"Aoki","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101901_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/jhg.2017.57","article-title":"Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy","volume":"62","author":"Nakamura","year":"2017","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.xcrm.2024.101901_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.xcrm.2024.101901_bib21","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/mtna.2014.76","article-title":"Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice","volume":"4","author":"Echigoya","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2024.101901_bib22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3233\/JND-200560","article-title":"Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases","volume":"8","author":"Aoki","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101901_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2024.101901_bib25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib26","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2024.101901_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2024.101901_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2024.101901_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2024.101901_bib33","series-title":"FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation","year":"2021"},{"key":"10.1016\/j.xcrm.2024.101901_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Shieh. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xcrm.2024.101901_bib29","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.xcrm.2024.101901_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JND-220811","article-title":"Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy","volume":"9","author":"Clemens","year":"2022","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib31","first-page":"235","article-title":"Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience","volume":"13","author":"Roshmi","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101901_bib35","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","article-title":"Highly efficient in\u00a0vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice","volume":"22","author":"Aoki","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2024.101901_bib36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ana.24365","article-title":"Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45","volume":"77","author":"Findlay","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2024.101901_bib37","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.mt.6300095","article-title":"Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript","volume":"15","author":"Wilton","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101901_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102034","article-title":"Exon 44 skipping in Duchenne muscular dystrophy: NS-089\/NCNP-02, a dual-targeting antisense oligonucleotide","volume":"34","author":"Watanabe","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2024.101901_bib39","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/s41598-019-40421-z","article-title":"Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride","volume":"9","author":"Takizawa","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101901_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117337","article-title":"Highly sensitive screening of antisense sequences for different types of DMD mutations in patients\u2019 urine-derived cells","volume":"423","author":"Takizawa","year":"2021","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.xcrm.2024.101901_bib41","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1093\/hmg\/ddu366","article-title":"Discovery of serum protein biomarkers in the mdx mouse model and crossspecies comparison to Duchenne muscular dystrophy patients","volume":"23","author":"Hathout","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2024.101901_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2019.04.005","article-title":"Titin in muscular dystrophy and cardiomyopathy: urinary titin as a novel marker","volume":"495","author":"Misaka","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.xcrm.2024.101901_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101901_bib44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2024.101901_bib45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","article-title":"Improved diagnosis of Becker muscular dystrophy by dystrophin testing","volume":"39","author":"Hoffman","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2024.101901_bib46","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","article-title":"Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human","volume":"17","author":"Neri","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2024.101901_bib47","article-title":"on behalf on the International DMD group, Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53","volume":"14","author":"Brogna","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101901_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","article-title":"Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping","volume":"71","author":"Anthony","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2024.101901_bib49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-021-01837-x","article-title":"National DMD Research Network of \u201cOne City, One Doctor\u201d. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib50","article-title":"Systemic inflammation in Duchenne muscular dystrophy: association with muscle function and nutritional status","volume":"2015","author":"Odel","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.xcrm.2024.101901_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/elps.1150100707","article-title":"Elevated plasma levels of haptoglobin in Duchenne muscular dystrophy:electrophoretic variants in patients with a severe form of the disease","volume":"10","author":"John","year":"1989","journal-title":"Electrophoresis"},{"key":"10.1016\/j.xcrm.2024.101901_bib52","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nmd.2011.05.011","article-title":"Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)","volume":"21","author":"Nadarajah","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.xcrm.2024.101901_bib53","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddaa132","article-title":"Serum biomarkers associated with baseline clinical severity in young steroid-na\u00efve Duchenne muscular dystrophy boys","volume":"29","author":"Dang","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2024.101901_bib54","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/glia.24116","article-title":"Dystrophin deficiency affects human astrocyte properties and response to damage","volume":"70","author":"Lange","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.xcrm.2024.101901_bib55","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.3233\/JND-210701","article-title":"Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy","volume":"8","author":"Benny Klimek","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2024.101901_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ppul.22536","article-title":"Development of reference equations for spirometry in japanese children aged 6\u201318 years","volume":"48","author":"Takase","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.xcrm.2024.101901_bib57","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/npr2.12335","article-title":"Systemic administration of the antisense oligonucleotide NS-089\/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: study protocol for a phase I\/II clinical trial","volume":"43","author":"Ishizuka","year":"2023","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.xcrm.2024.101901_bib58","doi-asserted-by":"crossref","first-page":"e1540","DOI":"10.1212\/WNL.0000000000201626","article-title":"PRO-DMD-01, The UK NorthStar Clinical Network, CCHMC, and The DMD Italian Group, DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials","volume":"100","author":"Muntoni","year":"2023","journal-title":"Neurology"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124006724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124006724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T04:11:27Z","timestamp":1740888687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124006724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666379124006724"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101901","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101901"}}